Drew Maclean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Drew Maclean has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Sachin Modi
University Hospital Southampton
4 shared publications - Timothy Bryant
Department of Interventional Radiology, University Hospital Southampton, Southampton, UK
4 shared publications - Mark Harris
Department of Urology, University Hospital Southampton, Southampton, UK
2 shared publications - Nigel Hacking
Department of Interventional Radiology, University Hospital Southampton, Southampton, UK
2 shared publications - B. Maher
University Hospital Southampton, Southampton General Hospital, Tremona Road, Southampton, Hampshire, SO16 6YD, UK
1 shared publication - Brian Stedman
Southampton University Hospitals NHS Trust
1 shared publication
Latest Publications
- 15 December 2024
- Published by Elsevier in Clinical Radiology
- Vol. 82, 106772
Identifying predictive markers for survival in malignant biliary obstruction following percutaneous transhepatic biliary drainage
- 15 December 2024
- Published by Elsevier in Clinical Radiology
- Vol. 82, 106772
Identifying predictive markers for survival in malignant biliary obstruction following percutaneous transhepatic biliary drainage
- 25 January 2023
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 46 (4) , 528-531
Mid-term Results of the Prospective LUMI-PAE Study: Propensity-Matched Analysis of 1-Year Follow-Up Data
- 25 January 2023
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 46 (4) , 528-531
Mid-term Results of the Prospective LUMI-PAE Study: Propensity-Matched Analysis of 1-Year Follow-Up Data
- 31 March 2020
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (6) , 897-903
Uterine Fibroid Embolization (UFE) with Optisphere: A Prospective Study of a New, Spherical, Resorbable Embolic Agent
Introduction Optisphere (Teleflex, Wayne, PA, USA, currently distributed by Medtronic, Minneapolis, MN, USA) is a new, resorbable, calibrated spherical embolic agent. We aimed to evaluate its clinical safety and effectiveness for fibroid embolization through a prospective case series. Method This prospective case series studied patients treated with fibroid embolization using Optisphere between July 2017 and June 2018. The primary outcomes were device-related adverse event assessments and MRI-determined percentage infarct of the dominant fibroid (DF %) and infarct of all fibroids (AF %) at 3 months post-embolization. Secondary outcomes included symptom improvement with the validated Uterine Fibroid Symptom Score and Quality of Life questionnaire (UFS-SS and UFS-QOL) at 3 months and 12 months post-embolization. Statistical analysis was through the Wilcoxon signed-rank test for nonparametric paired data. Results Twenty-three consecutive patients were treated with Optisphere (median age 44.0, uterine volume 484.0 ml, dominant fibroid volume 167.0 ml). The complete dominant fibroid infarction (DF %) rate was 91.3% (21/23 patients), and the complete all fibroid infarction rate (AF %) was 82.6% (19/23). No adverse device-related safety events were encountered. Significant improvement was demonstrated in 3-month UFS-SS (56 vs 19, p < 0.0001), UFS-QOL (40 vs 88, p = 0.0008), uterine volume (484 ml vs 246 ml, p < 0.0001) and dominant fibroid volume (167 vs 64 ml, p < 0.0001). Symptomatic improvement continued to 12 months (UFS-SS 56 vs 11, p = 0.0008, UFS-QOL 40 vs 98.7, p = 0.0008). Conclusion Optisphere is an effective embolic agent for fibroid embolization with good symptomatic response and percentage fibroid infarct.
- 31 March 2020
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (6) , 897-903
Uterine Fibroid Embolization (UFE) with Optisphere: A Prospective Study of a New, Spherical, Resorbable Embolic Agent
Introduction Optisphere (Teleflex, Wayne, PA, USA, currently distributed by Medtronic, Minneapolis, MN, USA) is a new, resorbable, calibrated spherical embolic agent. We aimed to evaluate its clinical safety and effectiveness for fibroid embolization through a prospective case series. Method This prospective case series studied patients treated with fibroid embolization using Optisphere between July 2017 and June 2018. The primary outcomes were device-related adverse event assessments and MRI-determined percentage infarct of the dominant fibroid (DF %) and infarct of all fibroids (AF %) at 3 months post-embolization. Secondary outcomes included symptom improvement with the validated Uterine Fibroid Symptom Score and Quality of Life questionnaire (UFS-SS and UFS-QOL) at 3 months and 12 months post-embolization. Statistical analysis was through the Wilcoxon signed-rank test for nonparametric paired data. Results Twenty-three consecutive patients were treated with Optisphere (median age 44.0, uterine volume 484.0 ml, dominant fibroid volume 167.0 ml). The complete dominant fibroid infarction (DF %) rate was 91.3% (21/23 patients), and the complete all fibroid infarction rate (AF %) was 82.6% (19/23). No adverse device-related safety events were encountered. Significant improvement was demonstrated in 3-month UFS-SS (56 vs 19, p < 0.0001), UFS-QOL (40 vs 88, p = 0.0008), uterine volume (484 ml vs 246 ml, p < 0.0001) and dominant fibroid volume (167 vs 64 ml, p < 0.0001). Symptomatic improvement continued to 12 months (UFS-SS 56 vs 11, p = 0.0008, UFS-QOL 40 vs 98.7, p = 0.0008). Conclusion Optisphere is an effective embolic agent for fibroid embolization with good symptomatic response and percentage fibroid infarct.
- 3 December 2019
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (3) , 459-465
The First 48 Consecutive Patients with 3-Year Symptom Score Follow-Up Post-Prostate Artery Embolization (PAE) at a Single-Centre University Hospital
Few studies on prostate artery embolization (PAE) follow patients up after 12 months. We aimed to evaluate the symptomatic efficacy of PAE in our patient cohort at 3 years.
- 3 December 2019
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (3) , 459-465
The First 48 Consecutive Patients with 3-Year Symptom Score Follow-Up Post-Prostate Artery Embolization (PAE) at a Single-Centre University Hospital
Few studies on prostate artery embolization (PAE) follow patients up after 12 months. We aimed to evaluate the symptomatic efficacy of PAE in our patient cohort at 3 years.